ORKA vs. CNTA, IDYA, MESO, AGIO, APGE, AMPH, TARS, IOVA, IRON, and IBRX
Should you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Centessa Pharmaceuticals (CNTA), IDEAYA Biosciences (IDYA), Mesoblast (MESO), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Amphastar Pharmaceuticals (AMPH), Tarsus Pharmaceuticals (TARS), Iovance Biotherapeutics (IOVA), Disc Medicine (IRON), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.
Oruka Therapeutics vs.
Oruka Therapeutics (NASDAQ:ORKA) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, community ranking, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Oruka Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500.
In the previous week, Centessa Pharmaceuticals had 3 more articles in the media than Oruka Therapeutics. MarketBeat recorded 6 mentions for Centessa Pharmaceuticals and 3 mentions for Oruka Therapeutics. Centessa Pharmaceuticals' average media sentiment score of 0.46 beat Oruka Therapeutics' score of 0.17 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.
Oruka Therapeutics' return on equity of -24.96% beat Centessa Pharmaceuticals' return on equity.
Oruka Therapeutics currently has a consensus target price of $43.17, indicating a potential upside of 232.56%. Centessa Pharmaceuticals has a consensus target price of $25.83, indicating a potential upside of 56.95%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Oruka Therapeutics is more favorable than Centessa Pharmaceuticals.
56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 22.7% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 11.6% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Centessa Pharmaceuticals received 17 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 57.69% of users gave Centessa Pharmaceuticals an outperform vote.
Oruka Therapeutics has higher earnings, but lower revenue than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Oruka Therapeutics beats Centessa Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Oruka Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oruka Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ORKA) was last updated on 1/22/2025 by MarketBeat.com Staff
